Videos

Dr. Mark Mattson intermittent fasting video series – exclusive discussion with Diabetes in Control In part one of this special interview, Dr. Mark Mattson and DIC publisher Steve Freed discuss Dr. Mattson’s research into brain aging and neurodegenerative disorders, and the positive effects of intermittent fasting in delaying aging and preventing …

This is part 3 of a 3-part video transcription. Transcript Part 1  |  Transcript Part 2  To view the video series, go here.   Steve Freed:               Right. So are there any books available that people that want to go on a diet that they kind of explain what to expect and so forth? …

This is part 2 of a 3-part video transcription. Transcript Part 1 | Transcript Part 3 To view the video series, go here. Steve Freed:               One of the things that I’ve noticed, which I think is comical, is we probably spend $50 billion to study that exercise is good for you. I …

This is part 1 of a 3-part video transcription. Transcript Part 2 | Transcript Part 3 To view the video series, go here. Steve Freed:               This is Steve Freed with Diabetes in Control and we have a special guest with us today. We’re here with Dr. Mark Mattson who is …

Bernstein’s Diabetes University Videos on YouTube  Our Advisory Board member, Dr. Richard K. Bernstein, has recently created, “Dr. Bernstein’s Diabetes University,” a complete course of video classes geared towards patients, which is now available on Youtube. Dr. Bernstein’s Diabetes University Playlist includes these short videos: “Basic Science of Diabetes,” “Values …

Dr. Christophe Arbet-Engels talks about how the empagliflozin study results were very positive in terms of lowering A1c, and goes over the basics of how the new class of SGLT-2 inhibitor drugs work, removing excess glucose, inducing some weight loss, and that there is potential for a decrease in blood pressure …

Christophe Arbet-Engels, MD, PhD, MBA, vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc., gives us a brief introduction to himself. Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. See more SGLT-2 Resources

Dr. Christophe Arbet-Engels, discusses some of the study results on empagliflozin in which more than 14,000 patients were involved in several different study configurations including monotherapy, empagliflozin as an add-on, and patients with renal impairment.   Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer …

Dr. Christophe Arbet-Engels explains how empagliflozin is being submitted to the FDA for treatment of diabetes indications and that there are different subgroups under this category. The FDA reviews the data and then may or may not grant approval or ask for more data. Christophe Arbet-Engels, MD, PhD, MBA, is vice …

Dr. Christophe Arbet-Engels discusses the clinical results of the empagliflozin studies focusing on the A1c drops which varied by study and were anywhere from .7 to 1% depending on the patient. He also differentiates between A1c drops due to weight loss and those due to the excretion of excess glucose which …